Vanadate enhances leptin-induced activation of JAK/STAT pathway in CHO cells

Biochemical and Biophysical Research Communications

Volumn 302, Issue 4, 2003, Pages 805-809

  Kita, Atsushi ^a   Uotani, Shigeo ^a   Kuwahara, Hironaga ^a   Takahashi, Ryoko ^a   Oshima, Katsuya ^a   Yamasaki, Hironori ^a   Mizuguchi, Hiroyuki ^b   Hayakawa, Takao ^b   Nagayama, Yuji ^a   Yamaguchi, Yoshihiko ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; LUCIFERASE; PROTEIN; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; VANADIC ACID;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 0037459158     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00264-X     Document Type: Article

References (38)

1. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:1994;425-432.
2. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:1995;543-546.
3. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G.J., Campfield L.A., Clark F.T., Deeds J. Identification and expression cloning of a leptin receptor, OB-R. Cell. 83:1995;1263-1271.
4. Lee G.H., Proenca R., Montez J.M., Carroll K.M., Darvishzadeh J.G., Lee J.I., Friedman J.M. Abnormal splicing of the leptin receptor in diabetic mice. Nature. 379:1996;632-635.
5. Baumann H., Morella K.K., White D.W., Dembski M., Bailon P.S., Kim H., Lai C.F., Tartaglia L.A. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc. Natl. Acad. Sci. USA. 93:1996;8374-8378.
6. Vaisse C., Halaas J.L., Horvath C.M., Darnell J.E. Jr., Stoffel M., Friedman J.M. Leptin activation of STAT3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat. Genet. 1:1996;95-97.
7. Montague C.T., Farooqi I.S., Whitehead J.P., Soos M.A., Rau H., Wareham N.J., Sewter C.P., Digby J.E., Mohammed S.N., Hurst J.A., Cheetham C.H., Earley A.R., Barnett A.H., Prins J.B., O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 387:1997;903-908.
8. Clement K., Vaisse C., Lahlou N., Cabrol S., Pelloux V., Cassuto D., Gourmelen M., Dina C., Chambaz J., Lacorte J.M., Basdevant A., Bougneres P., Lebouc Y., Froguel P., Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 392:1998;398-401.
9. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L., Caro J.F. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334:1996;292-295.
10. Schwartz M.W., Peskind E., Raskind M., Boyko E.J., Porte D. Jr. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat. Med. 2:1996;589-593.
11. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A., Hilton D.J. A family of cytokine-inducible inhibitors of signalling. Nature. 387:1997;917-921.
12. Bjorbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., Flier J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell. 1:1998;619-625.
13. Feng G.S., Hui C.C., Pawson T. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science. 259:1993;1607-1611.
14. Carpenter L.R., Farruggella T.J., Symes A., Karow M.L., Yancopoulos G.D., Stahl N. Enhancing leptin response by preventing SH2-containing phosphatase 2 interaction with Ob receptor. Proc. Natl. Acad. Sci. USA. 95:1998;6061-6066.
15. Swarup G., Speeg K.V. Jr., Cohen S., Garbers D.L. Phosphotyrosyl-protein phosphatase of TCRC-2 cells. J. Biol. Chem. 257:1982;7298-7301.
16. Shechter Y., Karlish S.J. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature. 284:1980;556-558.
17. Heyliger C.E., Tahiliani A.G., McNeill J.H. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science. 227:1985;1474-1477.
18. Ueno A., Arakaki N., Takeda Y., Fujio H. Inhibition of tyrosine autophosphorylation of the solubilized insulin receptor by an insulin-stimulating peptide derived from bovine serum albumin. Biochem. Biophys. Res. Commun. 144:1987;11-18.
19. Lawson A.E., Bao H., Wickrema A., Jacobs-Helber S.M., Sawyer S.T. Phosphatase inhibition promotes antiapoptotic but not proliferative signaling pathways in erythropoietin-dependent HCD57 cells. Blood. 96:2000;2084-2092.
20. Uotani S., Bjorbaek C., Tornoe J., Flier J.S. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes. 48:1999;279-286.
21. Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I., Sasaki M., Johnston J.A., Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells. 4:1999;339-351.
22. Mizuguchi H., Kay M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene. Ther. 10:1999;2013-2017.
23. Koizumi N., Mizuguchi H., Hosono T., Ishii-Watabe A., Uchida E., Utoguchi N., Watanabe Y., Hayakawa T. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochim. Biophys. Acta. 1568:2001;13-20.
24. Auernhammer C.J., Bousquet C., Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. Natl. Acad. Sci. USA. 96:1999;6964-6969.
25. Yamakawa K., Yamasaki H., Ozaki M., Yamauchi M., Fujita N., Abe T., Miyazoe H., Sera Y., Uotani S., Kawasaki E., Takino H., Yamaguchi Y., Eguchi K. Hepatocyte nuclear factor-1α inhibits insulin promoter factor 1-dependent transactivation of the human insulin gene. Endocr. Res. 27:2001;63-74.
26. Meyerovitch J., Rothenberg P., Shechter Y., Bonner-Weir S., Kahn C.R. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J. Clin. Invest. 87:1991;1286-1294.
27. Brichard S.M., Okitolonda W., Henquin J.C. Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology. 123:1988;2048-2053.
28. Witthuhn B.A., Quelle F.W., Silvennoinen O., Yi T., Tang B., Miura O., Ihle J.N. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 74:1993;227-236.
29. Wakao H., Harada N., Kitamura T., Mui A.L., Miyajima A. Interleukin2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J. 14:1995;2527-2535.
30. Imbert V., Renauld P.R. Duration of STAT5 activation influences the response of interleukin-2 receptor α gene to different cytokines. Eur. Cytokine Netw. 10:1999;71-78.
31. Bardgette J., Abboud H.E., Choudhury G.G. Activation of STAT1 α by phosphatase inhibitor vanadate in glomerular mesangial cells: involvement of tyrosine and serine phosphorylation. J. Recept. Signal Transduct. Res. 19:1999;865-884.
32. Migone T.S., Cacalano N.A., Taylor N., Yi T., Waldmann T.A., Johnston J.A. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc. Natl. Acad. Sci. USA. 95:1998;3845-3850.
33. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G., Lodish H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 80:1995;729-738.
34. Bjorbak C., Lavery H.J., Bates S.H., Olson R.K., Davis S.M., Flier J.S., Myers M.G. Jr. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J. Biol. Chem. 275:2000;40649-40657.
35. Frederich R.C., Lollmann B., Hamann A., Napolitano-Rosen A., Kahn B.B., Lowell B.B., Flier J.S. Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J. Clin. Invest. 96:1995;1658-1663.
36. Bjorbaek C., El-Haschimi K., Frantz J.D., Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J. Biol. Chem. 274:1999;30059-30065.
37. Degawa-Yamauchi M., Uotani S., Yamaguchi Y., Takahashi R., Abe T., Kuwahara H., Yamasaki H., Eguchi K. Ethanol inhibits leptin-induced STAT3 activation in Huh7 cells. FEBS Lett. 525:2002;116-120.
38. Bjorbak C., Lavery H.J., Bates S.H., Olson R.K., Davis S.M., Flier J.S., Myers M.G. Jr. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J. Biol. Chem. 275:2000;40649-40657.